The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma

References

• Amiot L, Vu N, Samson M. (2015). Biology of the immunomodulatory molecule HLA-G in human liver diseases. J Hepatol, 62, 1430–1437. doi:10.1016/j.jhep.2015.03.007
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. (1998). Dendritic cells and the control of immunity. Nature, 392, 245–252. doi:10.1038/32588
   PubMed Web of Science ®Google Scholar
• Brown D, Trowsdale J, Allen R. (2004). The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens, 64, 215–225. doi:10.1111/j.0001-2815.2004.00290.x
   PubMed Web of Science ®Google Scholar
• Bryant CE, Sutherland S, Kong B, et al. (2019). Dendritic cells as cancer therapeutics. Semin Cell Dev Biol, 86, 77–88. dio:10.1016/j.semcdb.2018.02.015
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity, 39, 1–10. doi:10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Chu CC, Ali N, Karagiannis P, et al. (2012). Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med, 209, 935–945. doi:10.1084/jem.20112583
   PubMed Web of Science ®Google Scholar
• Colletti NJ, Liu H, Gower AC, et al. (2016). TLR3 signaling promotes the induction of unique human BDCA-3 dendritic cell populations. Front Immunol, 7, 88. doi:10.3389/fimmu.2016.00088
   PubMed Web of Science ®Google Scholar
• Colonna M, Nakajima H, Cella M. (2000). A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol, 12, 121–127. doi:10.1006/smim.2000.0214
   PubMed Web of Science ®Google Scholar
• El-Serag HB. (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118–1127. doi:10.1056/NEJMra1001683
   PubMed Web of Science ®Google Scholar
• Elwan N, Salem ML, Kobtan A, et al. (2017). High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients. Immunol Invest, 47, 169–180. doi:10.1080/08820139.2017.1407787
   PubMed Web of Science ®Google Scholar
• Guilliams M, Ginhoux F, Jakubzick C, et al. (2014). Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol, 14, 571–578. doi:10.1038/nri3712
   PubMed Web of Science ®Google Scholar
• Kelly A, Fahey R, Fletcher JM, et al. (2014). CD141(+) myeloid dendritic cells are enriched in healthy human liver. J Hepatol, 60, 135–142. doi:10.1016/j.jhep.2013.08.007
   PubMed Web of Science ®Google Scholar
• Maccalli C, Parmiani G, Ferrone S. (2017). Immunomodulating and immunoresistance properties of cancer-initiating cells: implications for the clinical success of immunotherapy. Immunol Invest, 46, 221–238. doi:10.1080/08820139.2017.1280051
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Munster DJ, Clark GJ, et al. (2002). Characterization of human blood dendritic cell subsets. Blood, 100, 4512–4520. doi:10.1182/blood-2001-11-0097
   PubMed Web of Science ®Google Scholar
• Manavalan JS, Rossi PC, Vlad G, et al. (2003). High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol, 11, 245–258. doi:10.1016/S0966-3274(03)00058-3
   PubMed Web of Science ®Google Scholar
• Nizzoli G, Krietsch J, Weick A, et al. (2013). Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood, 122, 932–942. doi:10.1182/blood-2013-04-495424
   PubMed Web of Science ®Google Scholar
• O’Keeffe M, Mok WH, Radford KJ. (2015). Human dendritic cell subsets and function in health and disease. Cell Mol Life Sci, 72, 4309–4325. doi:10.1007/s00018-015-2005-0
   PubMed Web of Science ®Google Scholar
• Obeid JM, Kunk PR, Zaydfudim VM, et al. (2018). Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol ImmunoTher, 67, 161–174. doi:10.1007/s00262-017-2082-z
   PubMed Web of Science ®Google Scholar
• Prieto J, Melero I, Sangro B. (2015). Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 12, 681–700. doi:10.1038/nrgastro.2015.173
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, et al. (2018). The immunology of hepatocellular carcinoma. Nat Immunol, 19, 222–232. doi:10.1038/s41590-018-0044-z
   PubMed Web of Science ®Google Scholar
• Ristich V, Zhang W, Liang S, Horuzsko A. (2007). Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells. Hum Immunol, 68, 264–271. doi:10.1016/j.humimm.2006.11.008
   PubMed Web of Science ®Google Scholar
• Shang N, Figini M, Shangguan J, et al. (2017). Dendritic cells based immunotherapy. Am J Cancer Res, 7, 2091–2102.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. (2015). Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell, 161, 205–214. doi:10.1016/j.cell.2015.03.030
   PubMed Web of Science ®Google Scholar
• Shiroishi M, Tsumoto K, Amano K, et al. (2003). Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A, 100, 8856–8861. doi:10.1073/pnas.1431057100
   PubMed Web of Science ®Google Scholar
• Shortman K, Liu YJ. (2002). Mouse and human dendritic cell subtypes. Nat Rev Immunol, 2, 151–161. doi:10.1038/nri746
   PubMed Web of Science ®Google Scholar
• Steinman RM. (1991). The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 9, 271–296. doi:10.1146/annurev.iy.09.040191.001415
   PubMed Web of Science ®Google Scholar
• Watchmaker PB, Lahl K, Lee M, et al. (2014). Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nat Immunol, 15, 98–108. doi:10.1038/ni.2768
   PubMed Web of Science ®Google Scholar
• Wu L, Dakic A. (2004). Development of dendritic cell system. Cell Mol Immunol, 1, 112–118.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zheng J, Kang X, et al. (2015). Inhibitory leukocyte immunoglobulin-like receptors in cancer development. Sci China Life Sci, 58, 1216–1225. doi:10.1007/s11427-015-4925-1
   PubMed Web of Science ®Google Scholar